D
Dominik Witzigmann
Researcher at University of British Columbia
Publications - 60
Citations - 5135
Dominik Witzigmann is an academic researcher from University of British Columbia. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 21, co-authored 49 publications receiving 2577 citations. Previous affiliations of Dominik Witzigmann include University of Basel & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications.
TL;DR: In this review, state-of-the-art nanoparticles and targeted systems that have been investigated in clinical studies are discussed and the challenges faced in using nanomedicine products and translating them from a preclinical level to the clinical setting are emphasized.
Journal ArticleDOI
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akin Akinc,Martin Maier,Muthiah Manoharan,Kevin Fitzgerald,Muthusamy Jayaraman,Scott A Barros,Steven M. Ansell,Xinyao Du,Michael J. Hope,Thomas D. Madden,Barbara L. Mui,Sean C. Semple,Ying K. Tam,Marco A. Ciufolini,Dominik Witzigmann,Jayesh A. Kulkarni,Roy van der Meel,Pieter R. Cullis +17 more
TL;DR: The regulatory approval of Onpattro, a lipid nanoparticle-based short interfering RNA drug for the treatment of polyneuropathies induced by hereditary transthyretin amyloidosis, paves the way for clinical development of many nucleic acid-based therapies enabled by nanoparticle delivery.
Journal ArticleDOI
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.
Linde Schoenmaker,Dominik Witzigmann,Jayesh A. Kulkarni,Rein Verbeke,Gideon F.A. Kersten,Wim Jiskoot,Daan J.A. Crommelin +6 more
TL;DR: In this article, the authors discuss the structure of mRNA-LNPs, factors that impact their stability, and strategies to optimize them to improve the product stability of COVID-19 vaccines.
Journal ArticleDOI
The current landscape of nucleic acid therapeutics.
Jayesh A. Kulkarni,Dominik Witzigmann,Sarah B. Thomson,Sam Chen,Blair R. Leavitt,Pieter R. Cullis,Roy van der Meel +6 more
TL;DR: In this article, the authors review four platform technologies that have enabled the clinical translation of nucleic acid therapeutics: antisense oligonucleotides, ligand-modified small interfering RNA conjugates, lipid nanoparticles and adeno-associated virus vectors.
Journal ArticleDOI
PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application.
TL;DR: This review discusses state‐of‐the‐art nanomedicines based on PEG‐PCL that have been investigated in a preclinical setting and highlights recent therapeutic applications investigated in vitro and in vivo using advanced systems such as triggered release, multi‐component therapies, theranostics, or gene delivery systems.